NDA 219293 · Azurity
Danziten
Nilotinib Tartrate · Oral · Kinase Inhibitor
Last checked: Nov 19, 2026Latest source record: Apr 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Nov 7, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
185
34 Phase 3, 10 recruiting
FAERS reports
4,215
3,850 serious, 638 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: QT PROLONGATION and SUDDEN DEATHS • Nilotinib prolongs the QT interval. Prior to DANZITEN administration and periodically, monitor for hypokalemia or hypomagnesemia and correct deficiencies [ see Warnings and Precautions ( 5.3 ) ]. Obtain ECGs to monitor the QTc at baseline, seven days after initiation, and periodically thereafter, and following any dose adjustments [ see Warnings and Precautions ( 5.3 , 5.4 , 5.8 , 5.12 ) ]. • Sudden deaths have been reported in patients receiving nilotinib [ see Warnings and Precautions ( 5.4 ) ]. Do not administer DANZITEN tablets to patients with hypokalemia, hypomagnesemia, or long QT syndrome [ see Contraindications (4), Warnings and Precautions ( 5.3 ) ]. • Avoid use of concomitant drugs known to prolong the QT interval and strong CYP3A4 inhibitors [ see Drug Interactions ( 7.1 , 7.2 ) ]. WARNING: QT PROLONGATION and SUDDEN DEATHS See...
What it is approved for
From the label in effect Jul 28, 2025.
DANZITEN is a kinase inhibitor indicated for the treatment of: • Adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) • Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib. ( 1.2 ) 1.1 Adult Patients with Newly Diagnosed Ph+ CML-CP DANZITEN is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Additional pediatric use information is approved for Novartis Pharmaceuticals Corporation’s Tasigna ® (nilotinib) capsules. However, due to Novartis Pharmaceuticals Corporation’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. 1.2 Adult Patients with Resistant or Intolerant Ph+ CML-CP and CML-AP DANZITEN is indicated for the treatment of adult patients with chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) resistant or intolerant to prior therapy that included imatinib. Additional pediatric use information is approved for Novartis Pharmaceuticals Corporation’s Tasigna ® (nilotinib) capsules. However, due to Novartis Pharmaceuticals Corporation’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
Mechanism: Nilotinib is an inhibitor of the BCR-ABL kinase. Nilotinib binds to and stabilizes the inactive conformation of the kinase domain of ABL protein. In vitro, nilotinib inhibited BCR-ABL mediated proliferation of murine leukemic cell lines and human cell lines derived from patients with Ph+ CML. Under the conditions of the assays, nilotinib was able to overcome imatinib resistance resulting from BCR-ABL kinase mutations, in 32 out of 33 mutations tested. Nilotinib inhibited the autophosphorylation of the following kinases at IC50 values as indicated: BCR-ABL (20 to 60 nM), PDGFR (69 nM), c-KIT...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- DANZITEN · NILOTINIB TARTRATE EQ 95MG BASE · TABLET, ORAL · Prescription
- DANZITEN · NILOTINIB TARTRATE EQ 71MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Nilotinib" as an intervention, any sponsor and status, largest first.
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT05564377 · 2,900 participants (planned) · Start Apr 7, 2023 · Primary completion Jul 1, 2030
Drug: Alpelisib; Binimetinib and 13 more · For: Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8 and 12 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 484 sites in all
The Netherlands Cancer InstituteAcademic, hospital or other
NCT02925234 · 1,550 participants (planned) · Start Aug 2016 · Primary completion Sep 2027
Drug: Panitumumab; Olaparib and 35 more · For: Cancer; Tumors; Neoplasm and 1 more
Sites: Alkmaar, Netherlands; Almelo, Netherlands; Amersfoort, Netherlands · 36 sites in all
- Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's DiseasePivotal-lookingStatus unknown
KeifeRx, LLCIndustry
NCT05143528 · 1,275 participants (planned) · Start Feb 1, 2022 · Primary completion Dec 31, 2025
Drug: Nilotinib BE 84mg; Nilotinib BE 112 mg and 1 more · For: Alzheimer Disease
Novartis PharmaceuticalsNovartis (NVS)
NCT01061177 · 1,090 participants · Start May 2010 · Primary completion Jul 2014
Drug: Nilotinib · For: CML in Chronic Phase
Sites: Wels, Austria; Graz, Austria; Innsbruck, Austria · 320 sites in all
- Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatmentPivotal-lookingRecruiting
Centre Leon BerardAcademic, hospital or other
NCT02029001 · 900 participants (planned) · Start Mar 2014 · Primary completion Jan 2028
Drug: Nilotinib (400 mg BID); Everolimus (10 mg QD) and 4 more · For: Malignant Solid Neoplasms
Sites: Bordeaux, France; Lyon, France; Marseille, France · 7 sites in all
- A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00471497 · 846 participants · Start Jul 31, 2007 · Primary completion Sep 2, 2009
Drug: nilotinib; imatinib · For: Myelogenous Leukemia, Chronic
Sites: Los Angeles, California; San Diego, California; Vallejo, California · 213 sites in all
- TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER StudyPivotal-lookingCompleted
University of JenaAcademic, hospital or other
NCT01657604 · 717 participants · Start Aug 24, 2012 · Primary completion May 31, 2022
Drug: Peginterferon α2b; Nilotinib · For: Chronic Myeloid Leukemia
Sites: Brno, Czechia; Aachen, Germany; Amberg, Germany · 112 sites in all
- A Study of Nilotinib Versus Imatinib in GIST PatientsPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00785785 · 644 participants · Start Mar 2009 · Primary completion Oct 2014
Drug: Nilotinib (AMN107); imatinib (STI571) · For: Gastrointestinal Stromal Tumor (GIST)
Sites: Birmingham, Alabama; Flagstaff, Arizona; Duarte, California · 165 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug intolerance430
- drug ineffective354
- fatigue353
- drug resistance349
- diarrhoea344
- dyspnoea338
- nausea317
- headache311
- myalgia284
- arthralgia282
- abdominal pain274
- pleural effusion274
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 4 |
| 2008 | 12 |
| 2009 | 17 |
| 2010 | 19 |
| 2011 | 43 |
| 2012 | 95 |
| 2013 | 88 |
| 2014 | 154 |
| 2015 | 157 |
| 2016 | 215 |
| 2017 | 177 |
| 2018 | 267 |
| 2019 | 440 |
| 2020 | 375 |
| 2021 | 347 |
| 2022 | 323 |
| 2023 | 306 |
| 2024 | 365 |
| 2025 | 386 |
| 2026 | 425 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.
Kantarjian HM, Hughes TP, Larson RA, et al. · Leukemia 2021 · Comparative Study, Randomized Controlled Trial
- Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis.
Ortolan A, Webers C, Sepriano A, et al. · Ann Rheum Dis 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Drug-associated pulmonary arterial hypertension.
McGee M, Whitehead N, Martin J, et al. · Clin Toxicol (Phila) 2018 · Systematic Review
- Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.
Hochhaus A, Saglio G, Hughes TP, et al. · Leukemia 2016 · Comparative Study, Randomized Controlled Trial
- Nilotinib in Parkinson's disease: A systematic review and meta-analysis.
Xie X, Yuan P, Kou L, et al. · Front Aging Neurosci 2022 · Systematic Review
- Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia.
Chalandon Y, Rousselot P, Chevret S, et al. · Blood 2024 · Randomized Controlled Trial, Multicenter Study
Sponsor: Azurity
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.